Company intelligence / Profile preview

AATec Medical

Planegg-Martinsried, Bavaria, Germanyaatec-medical.com ↗

Ownership: Private
Development stage: Preclinical

Overview

AATec has robust preclinical safety and efficacy data for its lead candidate ATL‑105, an inhaled recombinant alpha‑1 antitrypsin therapy targeting neutrophilic airway inflammation. The company is preparing IND-enabling activities and expects to enter clinical trials by ~2026. The approach aims to maximize local therapeutic effect while minimizing systemic side effects.

Therapeutic areas: PulmonologyRare DiseasesInfectious Diseases
Modalities: Recombinant proteins (specifically recombinant alpha‑1 antitrypsin)Inhaled biologics/proteins
Industry: Biotech

Drug pipeline

1 asset

ATL-105

Preclinical

Partnerships

Beurer – device development/manufacturing partnership for inhaled drug products/delivery devicesSPRIND – funding partner via Germany’s Federal Agency for Disruptive Innovation

Beyond the preview

Go deeper on AATec Medical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AATec Medical.

Explore the full profile